PL2374453T3 - α-Pochodne cis-mononienasyconych kwasów tłuszczowych przeznaczone do stosowania jako lek - Google Patents

α-Pochodne cis-mononienasyconych kwasów tłuszczowych przeznaczone do stosowania jako lek

Info

Publication number
PL2374453T3
PL2374453T3 PL09831504T PL09831504T PL2374453T3 PL 2374453 T3 PL2374453 T3 PL 2374453T3 PL 09831504 T PL09831504 T PL 09831504T PL 09831504 T PL09831504 T PL 09831504T PL 2374453 T3 PL2374453 T3 PL 2374453T3
Authority
PL
Poland
Prior art keywords
cis
alpha
drug
derivatives
fatty acids
Prior art date
Application number
PL09831504T
Other languages
English (en)
Inventor
Ruiz Pablo Vicente Escribá
Xaubet Xavier Busquets
Coblijn Gwendolyn Barceló
Cañellas Victoria Lladó
Martínez Rafael Álvarez
Jiménez Silvia Teres
Daniel López
Estarellas Juana Barceló
Original Assignee
Univ Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2374453(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Illes Balears filed Critical Univ Illes Balears
Publication of PL2374453T3 publication Critical patent/PL2374453T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
PL09831504T 2008-12-09 2009-12-04 α-Pochodne cis-mononienasyconych kwasów tłuszczowych przeznaczone do stosowania jako lek PL2374453T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200803480A ES2342997B1 (es) 2008-12-09 2008-12-09 Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
PCT/ES2009/070561 WO2010066931A1 (es) 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento
EP09831504.7A EP2374453B1 (en) 2008-12-09 2009-12-04 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug

Publications (1)

Publication Number Publication Date
PL2374453T3 true PL2374453T3 (pl) 2015-07-31

Family

ID=42242375

Family Applications (3)

Application Number Title Priority Date Filing Date
PL18164265T PL3366285T3 (pl) 2008-12-09 2009-12-04 Alfa-pochodne cis-jednonienasyconych kwasów tłuszczowych do zastosowania jako leki
PL14195436T PL2842556T3 (pl) 2008-12-09 2009-12-04 Alfa-pochodne cis-jednonienasyconych kwasów tłuszczowych do stosowania jako leki
PL09831504T PL2374453T3 (pl) 2008-12-09 2009-12-04 α-Pochodne cis-mononienasyconych kwasów tłuszczowych przeznaczone do stosowania jako lek

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL18164265T PL3366285T3 (pl) 2008-12-09 2009-12-04 Alfa-pochodne cis-jednonienasyconych kwasów tłuszczowych do zastosowania jako leki
PL14195436T PL2842556T3 (pl) 2008-12-09 2009-12-04 Alfa-pochodne cis-jednonienasyconych kwasów tłuszczowych do stosowania jako leki

Country Status (18)

Country Link
US (3) US9000042B2 (pl)
EP (4) EP2842556B1 (pl)
JP (2) JP5711140B2 (pl)
KR (1) KR101683643B1 (pl)
CN (1) CN102355897B (pl)
AU (6) AU2009326993B2 (pl)
BR (1) BRPI0922870A8 (pl)
CA (1) CA2745052C (pl)
DK (3) DK2842556T3 (pl)
ES (5) ES2342997B1 (pl)
HU (2) HUE056170T2 (pl)
IL (1) IL213354A (pl)
MX (1) MX2011005978A (pl)
PL (3) PL3366285T3 (pl)
PT (4) PT2842556T (pl)
RU (1) RU2531353C2 (pl)
SI (1) SI3366285T1 (pl)
WO (1) WO2010066931A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342997B1 (es) 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
WO2011089265A1 (en) * 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2013132092A1 (en) 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
JP6348229B2 (ja) * 2014-10-21 2018-06-27 ユニバーシタット デ レス イレス バレアレス ヒドロキシ−トリグリセリドの合成方法、および疾患の予防および処置のためのその使用
CA3082144A1 (en) * 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
IL295120A (en) * 2020-01-29 2022-09-01 Univ Illes Balears alpha-hydroxylated fatty-acid metabolites, their medical uses and their use as biomarkers
ES2911474B2 (es) * 2020-11-17 2023-02-06 Univ Illes Balears Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
US12440467B2 (en) * 2021-12-09 2025-10-14 The Florida International University Board Of Trustees Treatment and prevention of infections using vegetable oil-derived polyols
ES2982396A1 (es) * 2023-03-14 2024-10-15 Veritas Therapeutics S L 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4928172B1 (pl) * 1969-10-27 1974-07-24
CH558321A (de) * 1971-08-03 1975-01-31 Ciba Geigy Ag Verfahren zur herstellung von carbonsaeuren bezw. carbonsaeuresalzen.
US3931306A (en) 1973-10-23 1976-01-06 International Flavors & Fragrances Inc. Process for producing isomer mixtures containing high proportions of cis-2-methyl-3-pentenoic acid
DE2448339A1 (de) * 1974-10-10 1976-04-22 Basf Ag Verfahren zur herstellung von olefinisch ungesaettigten carbonsaeureestern
DE2559201B2 (de) * 1975-12-30 1978-06-15 Hoechst Ag, 6000 Frankfurt Organozinnverbindungen und ihre Verwendung als Stabilisatoren
US4241097A (en) * 1979-09-13 1980-12-23 International Flavors & Fragrances Inc. Use of benzodionones in augmenting or enhancing the aroma and taste of a foodstuff
US4391757A (en) * 1981-11-27 1983-07-05 Carstab Corporation Organic antimony containing stabilizer compositions for halogenated polymers
JPS5899432A (ja) * 1981-12-09 1983-06-13 Maruzen Sekiyu Kagaku Kk 不飽和脂肪酸またはその塩およびそれからなる抗菌剤
US4551279A (en) * 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
FR2609032B1 (fr) * 1986-12-30 1990-01-05 Centre Nat Rech Scient Epoxydes fonctionnels enantiomeriquement purs, leur procede de preparation et leur application comme synthons chiraux
US4808403A (en) * 1987-03-17 1989-02-28 International Flavors & Fragrances Inc. Use of N,N-diethyl-m-toluamide and/or the ethyl ester of 2-methyl-3-pentenoic acid as insect attractants
US5504107A (en) * 1990-01-12 1996-04-02 The Ohio State University Research Foundation Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and pharmaceutical use thereof
GB9003201D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Cosmetic composition
US5208260A (en) * 1990-03-29 1993-05-04 G. D. Searle & Co. Vinyl Glycine derivatives for memory and learning enhancement or treatment of a cognitive disorder
US5198250A (en) 1990-07-16 1993-03-30 Lipotech Partners Limited Partnership Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
WO1992018116A1 (en) * 1991-04-10 1992-10-29 Yu Ruey J Compositions comprising 2-hydroxycarboxylic acids and related compounds, and methods for alleviating signs of dermatological aging
US6300373B1 (en) 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
JP3489703B2 (ja) * 1995-10-23 2004-01-26 株式会社ノエビア 微細エマルション組成物
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH10182338A (ja) * 1996-12-20 1998-07-07 Noevir Co Ltd 水中油型乳化組成物
AU740588B2 (en) * 1997-11-24 2001-11-08 Scripps Research Institute, The Inhibitors of gap junction communication
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
GB2385589A (en) * 2000-08-07 2003-08-27 Sofitech Nv Surfactant
ES2186576B1 (es) 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6702756B2 (en) * 2001-12-11 2004-03-09 University Technologies International Inc. Method and apparatus for diagnosing neurological impairment
RU2004125878A (ru) 2002-01-22 2005-05-27 Зингента Партисипейшнс Аг (Ch) Фенилзамещенные гетероциклические соединения, пригодные для применения в качестве гербицидов
US7462349B2 (en) * 2002-10-24 2008-12-09 Nurit Kalderon Beta interferon for the treatment of chronic spinal cord injury
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN102210852B (zh) * 2003-05-15 2016-10-19 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
KR100756890B1 (ko) * 2005-08-19 2007-09-07 경희대학교 산학협력단 신경세포 보호활성을 갖는 올레산을 함유하는 조성물
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
WO2009127009A1 (en) 2008-04-18 2009-10-22 Commonwealth Scientific And Industrial Research Organisation Condensation polymers
EP2265654A1 (en) * 2008-04-18 2010-12-29 Commonwealth Scientific and Industrial Research Organisation Polyurethanes
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.

Also Published As

Publication number Publication date
EP3366285B1 (en) 2021-06-30
KR20110126100A (ko) 2011-11-22
AU2016228171A1 (en) 2016-09-29
EP3366285A1 (en) 2018-08-29
IL213354A0 (en) 2011-07-31
EP2374453A1 (en) 2011-10-12
CA2745052A1 (en) 2010-06-17
EP2374453B1 (en) 2015-02-18
AU2009326993B2 (en) 2016-06-16
DK3366285T3 (da) 2021-10-04
ES2661412T3 (es) 2018-03-28
US10588883B2 (en) 2020-03-17
ES2342997A1 (es) 2010-07-20
EP2842555A2 (en) 2015-03-04
AU2018229472A1 (en) 2018-10-04
AU2016228167A1 (en) 2016-09-29
RU2011128335A (ru) 2013-01-20
DK2374453T3 (en) 2015-03-30
JP5711140B2 (ja) 2015-04-30
DK2842556T3 (en) 2018-03-26
WO2010066931A1 (es) 2010-06-17
ES2673406T3 (es) 2018-06-21
AU2019222955B2 (en) 2020-11-05
EP2842556B1 (en) 2018-01-31
EP2842556A2 (en) 2015-03-04
AU2019222955A1 (en) 2019-09-19
PT2374453E (pt) 2015-04-28
PT2842556T (pt) 2018-03-19
KR101683643B1 (ko) 2016-12-07
HUE056170T2 (hu) 2022-01-28
ES2535498T8 (es) 2016-08-19
PL3366285T3 (pl) 2022-01-10
CN102355897B (zh) 2014-06-04
EP2842556A3 (en) 2015-08-05
US9000042B2 (en) 2015-04-07
EP2374453A4 (en) 2012-05-30
ES2899274T3 (es) 2022-03-10
BRPI0922870A8 (pt) 2017-12-26
AU2018229472B2 (en) 2019-07-18
AU2018229474B2 (en) 2019-08-22
SI3366285T1 (sl) 2021-11-30
US20180193297A1 (en) 2018-07-12
MX2011005978A (es) 2011-10-11
EP2842555A3 (en) 2015-04-15
AU2018229474A1 (en) 2018-10-04
PL2842556T3 (pl) 2018-07-31
ES2535498T3 (es) 2015-05-12
JP2015061856A (ja) 2015-04-02
US20150297548A1 (en) 2015-10-22
US9730906B2 (en) 2017-08-15
IL213354A (en) 2017-06-29
ES2342997B1 (es) 2011-06-06
AU2009326993A1 (en) 2011-07-07
RU2531353C2 (ru) 2014-10-20
PT2842555T (pt) 2018-07-06
CN102355897A (zh) 2012-02-15
US20110294883A1 (en) 2011-12-01
JP2012511510A (ja) 2012-05-24
EP2842555B1 (en) 2018-04-18
CA2745052C (en) 2017-11-07
WO2010066931A4 (es) 2010-08-05
BRPI0922870A2 (pt) 2016-01-12
PT3366285T (pt) 2021-10-07
HUE037396T2 (hu) 2018-08-28

Similar Documents

Publication Publication Date Title
ZA201104036B (en) Fatty acids for use as a medicament
IL213354A0 (en) Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
PT2409963T (pt) Utilização de derivados de ácidos gordos polinsaturados como medicamentos
EP2459189A4 (en) FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS
EP2498602A4 (en) STABILIZED FORMULATIONS FROM FATTY ACIDS
AP3774A (en) A novel formulation of diclofenac
PL2799089T3 (pl) Process for preparing a pharmaceutical formulation of contrast agents
AP3659A (en) A novel formulation of meloxicam
GB2452358B (en) Preparation of bile acids
IL219535A0 (en) Syringes
IL210835A (en) Methods for the preparation of methyl ester of 4-oxo-octahydro-indole-1-carboxylic acid and its history
EP2542232A4 (en) FATTY ACID INHIBITORS
PL2358851T5 (pl) Zastosowanie kwasu metanosulfonowego do wytwarzania estrów kwasów tłuszczowych
GB0904300D0 (en) Essential fatty acid compounds
ZA201107378B (en) Process for the preparation of a biphenyl-2ylcarbamic acid ester
IL257014A (en) A novel formulation of meloxicam
AU2010903057A0 (en) Acetylenation of fatty acids
MY157821A (en) Synthesis of ascorbyl fatty acid ester